Participants with the highest body mass index (BMI) values (40 or above) were most likely to access semaglutide, which is not surprising given that this group has the highest risk for developing further metabolic diseasebut Podolsky says it reflects a trend that physicians may be restricting GLP-1 drugs to patients with the highest weight, and solely recommending lifestyle interventions to patients with BMI values of 35 or less
Complete this form to find out more
Current options, such as lifestyle modifications and bariatric surgery, have limited efficacy, highlighting the need for accessible pharmacological interventions
GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults With Obesity
Craving scores were significantly lower in the GLP-1RA group compared to the control group, as evidenced by a significant main effect of group ( 2 (1) = 4.71, p = 0.03, f = 0.58
Small-scale clinical trials have reported that exenatide and liraglutide can diminish gallbladder emptying or extend the time to reach the peak postprandial gallbladder ejection fraction [42,45]
